COVID-19 vaccine

Confidence in COVID-19 Vaccine in Older Adults Increasing, but Challenges in Registration and Access Continue

Retrieved on: 
Tuesday, March 9, 2021
Medicine, Medical specialties, COVID-19, COVID-19 vaccines, Vaccination, Vaccine, Virology, Medical research, Clinical trials, COVID-19 vaccine, Access to COVID-19 Tools Accelerator

However, only 22% believe they will have quick and easy access to a vaccine, emphasizing the need to reduce barriers to access to increase adoption among this population.

Key Points: 
  • However, only 22% believe they will have quick and easy access to a vaccine, emphasizing the need to reduce barriers to access to increase adoption among this population.
  • Round 1 coincided with Pfizer and Moderna both announcing the production of vaccines that are more than 90% effective at preventing COVID-19.
  • Round 2 closed just days ago now that more than 13% of the U.S. population, and nearly 50% of seniors, have received the vaccine.
  • Potential side effects continue to be the main reason influencing vaccine adoption or rejection,
    but significantly less than before.

VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902

Retrieved on: 
Tuesday, March 9, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical research, COVID-19 vaccine, Clinical trials, Health sciences, COVID-19 vaccines, Medicine, Articles, Adenoviridae, Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical research, COVID-19 vaccine, Clinical trials, Health sciences, COVID-19 vaccines, Medicine, Articles, Adenoviridae, VBI’s Coronavirus Vaccine Program: VBI-2900, Coronaviruses, VBI Vaccines Inc.

Todays news is a welcome development, bringing VBI one step closer to delivering a safe and effective COVID-19 vaccine for Canadians.

Key Points: 
  • Todays news is a welcome development, bringing VBI one step closer to delivering a safe and effective COVID-19 vaccine for Canadians.
  • Contingent upon rate of enrollment, the initial data from Phase 1 of this study are expected by the end of Q2 2021.
  • The execution of this adaptive Phase 1/2 study is supported by funding from the Strategic Innovation Fund of the Government of Canada.
  • Work remains ongoing to further optimize and manufacture VBI-2901, with a Phase 1/2 study initiation anticipated later in 2021.

Albertsons Companies Surpasses 1 Million COVID-19 Vaccine Doses Administered

Retrieved on: 
Tuesday, March 9, 2021
Retail, Health, Infectious diseases, Other Health, Supermarket, Pharmaceutical, Regions of the United States, Skaggs family, Albertsons, COVID-19 vaccine

Albertsons Companies is proud to announce that more than 1 million doses of COVID-19 vaccine have been administered to Americans nationwide through its trusted pharmacy teams.

Key Points: 
  • Albertsons Companies is proud to announce that more than 1 million doses of COVID-19 vaccine have been administered to Americans nationwide through its trusted pharmacy teams.
  • More information for the public about the COVID-19 vaccine including the scheduler for Albertsons Cos. pharmacies can be found at www.albertsons.com/COVID-19 .
  • In 2019 alone, along with the Albertsons Companies Foundation, the company gave $225 million in food and financial support.
  • In 2020, Albertsons Cos. made a $53 million commitment to community hunger relief efforts and a $5 million commitment to organizations supporting social justice.

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

Retrieved on: 
Monday, March 8, 2021
Clinical trials, COVID-19 vaccines, Medical specialties, Vaccination, Novavax, Drugs, Vaccine, NVX, COVID-19 vaccine

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Key Points: 
  • Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.
  • The companys proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.
  • Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
  • Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Government of Canada launches Vaccine Community Innovation Challenge to support increased vaccine confidence

Retrieved on: 
Monday, March 8, 2021
Medicine, Medical specialties, Health, Vaccination, Medical research, Vaccine, Virology, COVID-19 vaccine, Vaccines, Deployment of COVID-19 vaccines, Vaccine adverse event

The Government of Canada recognizes that community engagement plays a critical role in building vaccine confidence so everyone has the accurate information they need to make an informed decision on vaccination.

Key Points: 
  • The Government of Canada recognizes that community engagement plays a critical role in building vaccine confidence so everyone has the accurate information they need to make an informed decision on vaccination.
  • Community-driven engagement can more effectively influence vaccine confidence among communities who are underserved and have been disproportionately impacted by COVID-19.
  • The Challenge encourages people to help spread the word about COVID-19 vaccines and increase vaccine confidence through creative, community-driven and culturally sensitive means.
  • The Vaccine Community Innovation Challenge is one of several efforts by the Government of Canada to work with partners and stakeholders to increase vaccine confidence and address barriers to vaccine acceptance and uptake, including the Immunization Partnership Fund .

Amerijet delivers COVID-19 Vaccines

Retrieved on: 
Monday, March 8, 2021
Medical research, Companies, Health sciences, Life sciences, Amerijet International, Oxford–AstraZeneca COVID-19 vaccine, COVID-19 vaccine, Serum Institute of India, AstraZeneca, Vaccine

Amerijet delivered Covid-19 vaccines to the Caribbean and Central America on behalf of Odyssey Logistics Pvt.

Key Points: 
  • Amerijet delivered Covid-19 vaccines to the Caribbean and Central America on behalf of Odyssey Logistics Pvt.
  • These shipments were a part of India's Government gifted Covishield AstraZeneca vaccines manufactured by the Serum Institute of India.
  • The vaccines bound for Jamaica, Guyana, and Nicaragua, were transferred via Amerijet's Hub at the Miami International Airport.
  • The facility boasts exclusive airside ramp access to the Amerijet fleet for immediate loading and unloading of temperature-controlled shipments.

Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Retrieved on: 
Monday, March 8, 2021
Packaging, Health, Infectious diseases, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Medical research, Health sciences, Medicine, Vaccination, Health, COVID-19 vaccines, Clinical trials, RNA vaccines, Moderna COVID-19 vaccine, Fill and finish, COVID-19 vaccine, Vaccine, Baxter's BioPharma Solutions Business, Baxter, Moderna

Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.

Key Points: 
  • Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.
  • The manufacturing of the Moderna COVID-19 vaccine will take place at the BioPharma Solutions fill/finish sterile manufacturing facilities located in Bloomington, Ind.
  • We welcome the opportunity to work with Baxter BioPharma Solutions on fill/finish manufacturing for the Moderna COVID-19 Vaccine in the U.S., said Juan Andres, Modernas Chief Technical Operations and Quality Officer.
  • Baxter is a registered trademark and BioPharma Solutions is a trademark of Baxter International Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005514/en/

Federal Direction Requires Prioritization of All K-12 and Child Care Teachers and Personnel for COVID-19 Vaccine

Retrieved on: 
Monday, March 8, 2021
Primary, Secondary, Education, Other Health, Health, Supermarket, Women, Seniors, Pharmaceutical, MEN, Retail, Consumer, Health care, Health sciences, Companies, Medical research, Publix, COVID-19 vaccine, Johnson & Johnson, Vaccine

Publix will follow this new directive during its next COVID19 vaccine scheduling opportunity in Florida, Wednesday, March 10.

Key Points: 
  • Publix will follow this new directive during its next COVID19 vaccine scheduling opportunity in Florida, Wednesday, March 10.
  • After those in the prioritized group are finished making appointments, any remaining appointments will be available to other eligible individuals.
  • Publix Pharmacy has received its first shipment of the single-dose Johnson & Johnson COVID19 vaccine.
  • The online reservation system will open Wednesday, March 10, at 7 a.m. Eastern time for any individual who meets state and federal requirements, with priority given to school and child care teachers and personnel as directed by the federal government.

Global mRNA Vaccines Market Trajectory & Analytics Report 2021: Market to Reach $30.5 Billion by 2027, Displaying at a CAGR of -0.7% - ResearchAndMarkets.com

Retrieved on: 
Monday, March 8, 2021
Health, Infectious diseases, Medical research, COVID-19 vaccines, Medicine, Medical specialties, Health sciences, COVID-19 vaccine, Vaccine, RNA vaccine

World 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Years 2021, 2021 & 2027

Key Points: 
  • World 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Years 2021, 2021 & 2027
    World 6-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Years 2021, 2021 & 2027
    World 6-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Years 2021, 2021 & 2027
    World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for Years 2021, 2021 & 2027
    US mRNA Vaccines and Therapeutics Market Share (in %) by Company: 2020 & 2027
    Infection Disease Treatment (Type) Competitor Revenue Share (in %) in the US: 2020 & 2027
    Infection Prevention (Type) Market Share Breakdown (in %) of Major Players in the US: 2020 & 2027
    Individualized Cancer Treatment (Type) Market in the US: Percentage Breakdown of Revenues by Company for 2020 & 2027

SARS-CoV-2 (COVID-19) Vaccine: Global Market Analysis & Forecast to 2026 by Technology and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, March 8, 2021
Health, Infectious diseases, COVID-19 vaccines, COVID-19, Clinical trials, Health sciences, Medicine, Medical research, Vaccination, Adenoviridae, COVID-19 vaccine, Vaccine, Coronavirus disease, Johnson & Johnson COVID-19 vaccine

The "SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "SARS-CoV-2 COVID Vaccine Market Analysis & Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a comprehensive overview of the size of the SARS-CoV-2 (COVID-19) Vaccine market, segmentation of the industry (by geography and vaccine technology), key players and the vast potential of vaccines that are in clinical trials.
  • This analysis indicates that the global COVID-19 vaccine market was worth $59 billion in 2021.
  • The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026.